With the objective of radically changing chronic pain treatments, Paramedics Inc. is structured around development a novel class of small molecules that inhibit Protease-activated Receptor-2 (PAR-2), a receptor found in neurons, airway and immune cells, that generates cellular signals involved in inflammation and pain. Beginning in 2008 with the firm's first compound, the team has since developed hundreds of compounds that target specific molecules responsible for symptoms of asthma, pain, inflammation, and migraines â more accurate targeting results in less chance of side effects. The firm's first-in-class small molecules have the potential to fill an unmet need for treating airway inflammation and chronic pain, with reduced adverse effects, by targeting a receptor that directly promotes both conditions.
